UNIVERSITY OF ROCHESTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1850-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.rochester.edu
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
Phase 1
Recruiting
- Conditions
- Rheumatoid Arthritis
- Interventions
- Device: MultiSpectral Imaging System
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 40
- Registration Number
- NCT05197530
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Study of Sulphoraphane in Chronic Kidney Disease
Phase 1
Completed
- Conditions
- Chronic Kidney Disease stage3Chronic Kidney Disease stage4
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 18
- Registration Number
- NCT05153174
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye
Not Applicable
Not yet recruiting
- Conditions
- Dry Eye Syndromes
- Interventions
- Other: Platelet Poor Plasma Tear DropsOther: Platelet Rich Plasma Tear Drops
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 15
- Registration Number
- NCT05121493
- Locations
- 🇺🇸
Flaum Eye Institute at the University of Rochester, Rochester, New York, United States
Renal Denervation + PVI vs PVI Alone for Persistent AF
Not Applicable
Recruiting
- Conditions
- Atrial Fibrillation
- Interventions
- Device: catheter ablationDevice: renal artery denervation
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 50
- Registration Number
- NCT05116384
- Locations
- 🇺🇸
University of Rochester, Short Hills, New Jersey, United States
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
Phase 1
Withdrawn
- Conditions
- Cancer of LiverHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- University of Rochester
- Registration Number
- NCT05109052
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage
Not Applicable
Completed
- Conditions
- QuadrantanopiaVision Loss PartialHemianopiaHemianopia HomonymousStroke, Ischemic
- Interventions
- Other: Training in the Blind FieldOther: Training in the Sighted Field
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 280
- Registration Number
- NCT05098236
- Locations
- 🇺🇸
Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
Evaluating Deep Breathing in Health Participants Using a Device Called Impulse Oscillometry
Completed
- Conditions
- Lung Function DecreasedBreathing, Mouth
- Interventions
- Device: Impulse Oscillometer
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT05085795
- Locations
- 🇺🇸
Mary Parkes Asthma and Allergy Center, Rochester, New York, United States
Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer
Not Applicable
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: Experimental
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 10
- Registration Number
- NCT05073432
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
SP TLF Versus Ho:YAG Laser
Not Applicable
Completed
- Conditions
- Urinary Calculi
- Interventions
- Device: Laser lithotripsy (SP TLF)
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 62
- Registration Number
- NCT05048706
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸University of Rochester, Rochester, New York, United States
Decreasing Polypharmacy in Older Adults With Curable Cancers Trial
Phase 1
Recruiting
- Conditions
- Cancer
- Interventions
- Other: Pharmacist-led deprescribingOther: Patient education
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 80
- Registration Number
- NCT05046171
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
© Copyright 2025. All Rights Reserved by MedPath